### 2.2.1 In vitro and physico-chemical data

A literature search was performed to collect available information on physico-chemical properties of S- and R-omeprazole and summarized in [Table 1](#table-1) and [Table 2](#table-2), respectively.

| **Parameter**                                              | **Unit** | **Value**     | Source                                          | **Description**                                              |
| :--------------------------------------------------------- | -------- | ------------- | ----------------------------------------------- | ------------------------------------------------------------ |
| MW<sup>+</sup>                                             | g/mol    | 345.42        | [DrugBank DB00338](#5-references)               | Molecular weight.                                            |
| pK<sub>a,acid</sub><sup>+</sup>                            |          | 9.29          | [DrugBank DB00338](#5-references)               | Acidic dissociation constant                                 |
| pK<sub>a,base</sub><sup>+</sup>                            |          | 4.77          | [DrugBank DB00338](#5-references)               | Basic dissociation constant                                  |
| Solubility (pH)<sup>+</sup>                                | mg/mL    | 0.36<br />(7) | [DrugBank DB00338](#5-references)               | Aqueous Solubility                                           |
| logD                                                       |          | 2.23          | [Ogilvie 2011](#5-references)                   | Distribution coefficient                                     |
| fu<sup>+</sup>                                             | %        | 3             | [Nexium prescribing information](#5-references) | Fraction unbound in plasma                                   |
| Kinact  CYP2C19<sup>+</sup>                                | l/h      | 5             | [Wu 2014](#5-references)                        | Kinact of time dependent inhibition on CYP2C19               |
| K<sub>i</sub> CYP2C19<sup>+</sup>                          | µM       | 0.3           | [Wu 2014](#5-references)                        | KI of time dependent inhibition on CYP2C19                   |
| K<sub>i</sub> CYP2C19 (competitive inhibition)<sup>+</sup> | µM       | 3.1           | [Liu 2005](#5-references)                       | The total ki  value reported by Liu was 3.4 µmol/L and corrected with an fu_mic of 0.92 |
| Renal Elimination<sup>+</sup>                              | l/h      | 0.037         | [Wu 2014](#5-references)                        | Assumed same as omeprazole                                   |

**Table 1:**<a name="table-1"></a> Physico-chemical and *in-vitro* metabolization properties of S-omeprazole extracted from literature. *<sup>+</sup>: Value used in final model*



| **Parameter**                                              | **Unit** | **Value**     | Source                            | **Description**                                              |
| :--------------------------------------------------------- | -------- | ------------- | --------------------------------- | ------------------------------------------------------------ |
| MW<sup>+</sup>                                             | g/mol    | 345.42        | [DrugBank DB00338](#5-references) | Molecular weight.                                            |
| pK<sub>a,acid</sub><sup>+</sup>                            |          | 9.29          | [DrugBank DB00338](#5-references) | Acidic dissociation constant                                 |
| pK<sub>a,base</sub><sup>+</sup>                            |          | 4.77          | [DrugBank DB00338](#5-references) | Basic dissociation constant                                  |
| Solubility (pH)<sup>+</sup>                                | mg/mL    | 0.36<br />(7) | [DrugBank DB00338](#5-references) | Aqueous Solubility                                           |
| logD                                                       |          | 2.23          | [Ogilvie 2011](#5-references)     | Distribution coefficient                                     |
| fu<sup>+</sup>                                             | %        | 4             | [Ogilvie 2011](#5-references)     | Fraction unbound in plasma; assumed same as omeprazole       |
| Kinact  CYP2C19<sup>+</sup>                                | l/h      | 4             | [Wu 2014](#5-references)          | Kinact of time dependent inhibition on CYP2C19               |
| K<sub>i</sub> CYP2C19<sup>+</sup>                          | µM       | 1.6           | [Wu 2014](#5-references)          | KI of time dependent inhibition on CYP2C19                   |
| K<sub>i</sub> CYP2C19 (competitive inhibition)<sup>+</sup> | µM       | 5.3           | [Liu 2005](#5-references)         | The total ki  value reported by Liu was 5.7 µmol/L and corrected with an fu_mic of 0.92 |
| Renal Elimination<sup>+</sup>                              | l/h      | 0.037         | [Wu 2014](#5-references)          | Assumed same as omeprazole                                   |

**Table 2:**<a name="table-2"></a> Physico-chemical and *in-vitro* metabolization properties of R-omeprazole extracted from literature. *<sup>+</sup>: Value used in final model*

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on omeprazole in adults. Data used for model development and validation for omeprazole, S-omeprazole, and R-omeprazole are listed in [Table 3](#table-3), [Table 4](#table-4), and [Table 5](#table-5), respectively.

| **Source**           | **Route** | **Dose [mg]/**  **Schedule \*** | **Pop.**     | **Sex** | **N** | **Form.** | **Comment**                       |
| -------------------- | --------- | ------------------------------- | ------------ | ------- | ----- | --------- | --------------------------------- |
| [Andersson 1990](#5-references)<sup>+</sup> | i.v.      | 40 - 80                         | HV                        | M       | 10    | solution                      |                    |
| [Andersson 1990](#5-references)              | p.o.      | 40 - 80                         | HV                        | M       | 10    | Oral solution                 |                    |
| [Andersson 1991](#5-references)              | p.o.      | 10 - 20 – 40 q.d.               | HV                        | M       | 12    | e.c. granules                 |                    |
| [Andersson 1991](#5-references)<sup>+</sup>  | i.v.      | 10 - 20 - 40                    | HV                        | M       | 12    | solution                      |                    |
| [Andersson 1998](#5-references)              | p.o.      | 20 q.d.                         | HV                        | M       | 12    | capsule                       | EM                 |
| [Andersson 1998](#5-references)              | p.o.      | 20 q.d.                         | HV                        | M       | 2     | capsule                       | PM                 |
| [Oosterhuis 1992](#5-references)<sup>+</sup> | i.v.      | 40 - 80                         | HV                        | M       | 8     | solution                      |                    |
| [Uno 2007](#5-references)<sup>+</sup>        | i.v.      | 20                              | HV japanese               | M - F   | 6     | solution                      | hmEM               |
| [Uno 2007](#5-references)<sup>+</sup>        | i.v.      | 20                              | HV japanese               | M - F   | 6     | solution                      | PM                 |
| [Uno 2007](#5-references)                    | p.o.      | 40                              | HV japanese               | M - F   | 6     | tablet                        | hmEM               |
| [Uno 2007](#5-references)                    | p.o.      | 40                              | HV japanese               | M - F   | 6     | tablet                        | PM                 |
| [Regårdh 1990](#5-references)<sup>+</sup>    | i.v.      | 10                              | HV                        | M       | 8     | solution                      |                    |
| [Regårdh 1990](#5-references)                | p.o.      | 20                              | HV                        | M       | 8     | Oral solution                 |                    |
| [Andersson 2000](#5-references)              | p.o.      | 15 q.d.                         | HV                        | -       | 4     | Oral solution                 | EM                 |
| [Andersson 2000](#5-references)              | p.o.      | 60 q.d.                         | HV                        | -       | 5     | Oral solution                 | PM                 |
| [Hassan-Alin 2005](#5-references)            | p.o.      | 20 – 40 q.d.                    | HV                        | -       | -     | Oral solution                 |                    |
| [Cho 2002](#5-references)                    | p.o.      | 20                              | HV asian                  | -       | -     | capsule                       | EM +/- moclobemide |
| [Cho 2002](#5-references)                    | p.o.      | 20                              | HV asian                  | -       | -     | capsule                       | PM +/- moclobemide |
| [Yasui-Furukori 2004](#5-references)         | p.o.      | 40                              | HV japanese               | M - F   | 6     | omepral                       |                    |
| [Yasui-Furukori 2004](#5-references)         | p.o.      | 40                              | HV japanese               | M - F   | 6     | omepral                       | PM +/- fluvoxamine |
| [Wu 2016](#5-references)      | p.o.      | 40 q.d.                         | HV caucasian              | M - F   | 15    | gastro-resistant hard capsule |                    |

**Table 3:**<a name="table-3"></a> Literature sources of clinical concentration data of omeprazole used for model development and validation. *e.c.: enteric coated; -: respective information was not provided in the literature source; \*:single dose unless otherwise specified; EM: extensive metabolizers; PM: pooor metabolizers; <sup>+</sup>: Data used for final parameter identification*

| **Source**                                     | **Route** | **Dose [mg]/**  **Schedule \***                              | **Pop.** | **Sex** | **N** | **Form.**     | **Comment** |
| ---------------------------------------------- | --------- | ------------------------------------------------------------ | -------- | ------- | ----- | ------------- | ----------- |
| [Wilder-Smith 2005](#5-references)<sup>+</sup> | i.v.      | 40 q.d.                                                      | HV       | M - F   | 39    | solution      |             |
| [Wilder-Smith 2005](#5-references)<sup>+</sup> | p.o.      | 40 q.d.                                                      | HV       | M - F   | 37    | capsule       |             |
| [Hassan-Alin 2000](#5-references)<sup>+</sup>  | i.v.      | 20 - 40                                                      | HV       | -       | -     | solution      |             |
| [Andersson 2000](#5-references)                | p.o.      | 15 q.d.                                                      | HV       | -       | 4     | oral solution | EM          |
| [Andersson 2000](#5-references)<sup>+</sup>    | p.o.      | 60 q.d.                                                      | HV       | -       | 5     | oral solution | PM          |
| [Hassan-Alin 2005](#5-references)<sup>+</sup>  | p.o.      | 20 - 40 q.d.                                                 | HV       | -       | -     | oral solution |             |
| [FDA Nexium Review](#5-references)             | p.o.      | 40                                                           | HV       | M       | -     | -             | EM          |
| [FDA Nexium Review](#5-references)<sup>+</sup> | p.o.      | 40                                                           | HV       | M       | -     | -             | PM          |
| [Rohss 2007](#5-references)<sup>+</sup>        | i.v.      | 120mg(30min)+8mg/h - 120mg(2h)+8mg/h -  80mg(30min)+4mg/h - 80mg(30min)+8mg/h - 40mg(30min)+8mg/h | HV       | -       | 25    | solution      |             |

**Table 4:**<a name="table-4"></a> Literature sources of clinical concentration data of S-omeprazole used for model development and validation. *e.c.: enteric coated; -: respective information was not provided in the literature source; \*:single dose unless otherwise specified; EM: extensive metabolizers; PM: pooor metabolizers; <sup>+</sup>: Data used for final parameter identification*

| **Source**                                    | **Route** | **Dose [mg]/**  **Schedule \*** | **Pop.** | **Sex** | **N** | **Form.**     | **Comment** |
| --------------------------------------------- | --------- | ------------------------------- | -------- | ------- | ----- | ------------- | ----------- |
| [Andersson 2000](#5-references)<sup>+</sup>   | p.o.      | 15 q.d.                         | HV       | -       | 4     | oral solution | EM          |
| [Andersson 2000](#5-references)<sup>+</sup>   | p.o.      | 60 q.d.                         | HV       | -       | 5     | oral solution | PM          |
| [Hassan-Alin 2005](#5-references)<sup>+</sup> | p.o.      | 20 - 40 q.d.                    | HV       | -       | -     | oral solution |             |

**Table 5:**<a name="table-5"></a> Literature sources of clinical concentration data of R-omeprazole used for model development and validation. *e.c.: enteric coated; -: respective information was not provided in the literature source; \*:single dose unless otherwise specified; EM: extensive metabolizers; PM: pooor metabolizers; <sup>+</sup>: Data used for final parameter identification*